ROCHE-OSI2950G

Study Sponsor : Roche

Study Title

A Phase II Randomized, Double-Blind, Multi-Center Study of Avastin Plus Docetaxel or Tarceva versus Docetaxel or Tarceva Alone in Patients with Recurrent or Refractory Non-Small Cell Lung Carcinoma

Medicine or Vaccine (generic name)

erlotinib

Sponsor Identification Number

OSI2950G

Trial Registry Identification Number(#'s)

NCT00095225

Medical Condition

malignant neoplasm of bronchus and lung

Phase

Phase 2

Link to study details on the Roche Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

https://clinicaltrials.gov/ct2/show/NCT00095225?term=OSI2950G&rank=1

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

January 2016